NCCN VERSION 2 2015

NCCN Guidelines Version 2.2015 Breast Cancer

NCCN Guidelines Index Breast Cancer Table of Contents Discussion

References 1. Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA: A Cancer Journal for Clinicians 2014:n/a-n/a. Available at: http://dx.doi.org/10.3322/caac.21208 . 2. Desantis C, Ma J, Bryan L, Jemal A. Breast cancer statistics, 2013. 3. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005;365:1687-1717. Available at: http://www.ncbi.nlm.nih.gov/pubmed/15894097 . 4. Siegel R, Ward E, Brawley O, Jemal A. Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin 2011;61:212-236. Available at: http://www.ncbi.nlm.nih.gov/pubmed/21685461 . 5. Berry DA, Cronin KA, Plevritis SK, et al. Effect of screening and adjuvant therapy on mortality from breast cancer. N Engl J Med 2005;353:1784-1792. Available at: http://www.ncbi.nlm.nih.gov/pubmed/16251534 . 6. Gail MH, Costantino JP, Bryant J, et al. Weighing the risks and benefits of tamoxifen treatment for preventing breast cancer. J Natl 7. Dupont WD, Page DL. Risk factors for breast cancer in women with proliferative breast disease. N Engl J Med 1985;312:146-151. Available at: http://www.ncbi.nlm.nih.gov/pubmed/3965932 . 8. Dupont WD, Page DL. Risk factors for breast cancer in women with proliferative breast disease. N Engl J Med 1985;312:146-151. Available at: http://www.ncbi.nlm.nih.gov/pubmed/3965932 . CA Cancer J Clin 2014;64:52-62. Available at: http://www.ncbi.nlm.nih.gov/pubmed/24114568 . Cancer Inst 1999;91:1829-1846. Available at: http://www.ncbi.nlm.nih.gov/pubmed/10547390 .

9. Edge SB, Byrd DR, Compton CC, et al., eds. AJCC Cancer Staging Manual, 7th Edition. New York: Springer; 2010. 10. White J, Morrow M, Moughan J, et al. Compliance with breast- conservation standards for patients with early-stage breast carcinoma. Cancer 2003;97:893-904. Available at: http://www.ncbi.nlm.nih.gov/pubmed/12569588 . 11. Wilkinson NW, Shahryarinejad A, Winston JS, et al. Concordance with breast cancer pathology reporting practice guidelines. J Am Coll Surg 2003;196:38-43. Available at: http://www.ncbi.nlm.nih.gov/pubmed/12517547 . 12. Allred DC, Harvey JM, Berardo M, Clark GM. Prognostic and predictive factors in breast cancer by immunohistochemical analysis. immunohistochemical demonstration of oestrogen receptors in routine practice: interlaboratory variance in the sensitivity of detection and evaluation of scoring systems. J Clin Pathol 2000;53:125-130. Available at: http://www.ncbi.nlm.nih.gov/pubmed/10767828 . 14. Rudiger T, Hofler H, Kreipe HH, et al. Quality assurance in immunohistochemistry: results of an interlaboratory trial involving 172 pathologists. Am J Surg Pathol 2002;26:873-882. Available at: http://www.ncbi.nlm.nih.gov/pubmed/12131154 . 15. Allred DC, Carlson RW, Berry DA, et al. NCCN Task Force Report: Estrogen receptor and progesterone receptor testing in breast cancer by immunohistochemistry. J Natl Compr Canc Netw 2009;7 Suppl 6:S1- S21; quiz S22-23. Available at: http://www.ncbi.nlm.nih.gov/pubmed/19755043 . 16. Hammond MEH, Hayes DF, Dowsett M, et al. American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and Mod Pathol 1998;11:155-168. Available at: http://www.ncbi.nlm.nih.gov/pubmed/9504686 . 13. Rhodes A, Jasani B, Barnes DM, et al. Reliability of

Version 2.2015, 03/11/15 © National Comprehensive Cancer Network, Inc. 2015, All rights reserved. The NCCN Guidelines® and this illustration may not be reproduced in any form without the express written permission of NCCN®. MS-67